• Several new routine customers since EMA decision on anakinra
• We make some adjustments in our near-term forecast model
• We maintain our valuation interval of DKK 115.00 – 180.00 per share

ViroGates’ annual report showed that Q4 profits came in exactly as we had forecast, however both revenues and costs were slightly below our estimates. Total net revenue for 2021 still posted a 43 percent increase over 2020. The company is attracting more routine customers, especially since EMA’s decision to grant approval of suPAR guided anakinra treatment. We make some adjustments to our valuation model, realising that our near-term revenue forecasts were too optimistic. Our long-term scenario and our valuation interval of DKK 115.00 – 180.00 per share are, however, intact.

The full report is available here.